IP Verse

Pharmaceutical Anti-Tnf-Alpha Antibody Formulation - EP3212667

The patent EP3212667 was granted to Richter Gedeon Nyrt on Sep 19, 2018. The application was originally filed on Oct 28, 2015 under application number EP15808356A. The patent is currently recorded with a legal status of "Revoked".

EP3212667

RICHTER GEDEON NYRT
Application Number
EP15808356A
Filing Date
Oct 28, 2015
Status
Revoked
Apr 4, 2025
Publication Date
Sep 19, 2018
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions (3)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

SAMSUNG BIOEPISDec 12, 2019PATENT BOUTIQUEINTERVENTION WITHDRAWN
BIOGENJun 19, 2019PATENT BOUTIQUEWITHDRAWN
SAMSUNG BIOEPISJun 19, 2019PATENT BOUTIQUEWITHDRAWN

Patent Citations (10) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication Number
INTERNATIONAL-SEARCH-REPORTWO2004016286
INTERNATIONAL-SEARCH-REPORTWO2011104381
INTERNATIONAL-SEARCH-REPORTWO2013011076
INTERNATIONAL-SEARCH-REPORTWO2013164837
INTERNATIONAL-SEARCH-REPORTWO2013186230
INTERNATIONAL-SEARCH-REPORTWO2014039903
INTERNATIONAL-SEARCH-REPORTWO2014114651
OPPOSITIONWO2014039903
OPPOSITIONWO2014068021
OPPOSITIONWO2016066688

Non-Patent Literature (NPL) Citations (11) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference Text
EXAMINATION- "Alternative buffers for pharmaceutical anti-TNFalpha monoclonal antibody formulations [Elektronische Ressource]", PAPDEOTT00,, (20130206), page 10pp, XP009188701
INTERNATIONAL-SEARCH-REPORT- WANG W ET AL, "ANTIBODY STRUCTURE, INSTABILITY, AND FORMULATION", JOURNAL OF PHARMACEUTICAL SCIENCES, AMERICAN PHARMACEUTICAL ASSOCIATION, WASHINGTON, US, (20070101), vol. 96, no. 1, doi:10.1002/JPS.20727, ISSN 0022-3549, pages 1 - 26, XP009084505 [Y] 1-29 * page 9, column l, paragraph 3 *
OPPOSITION- "8.2.1. Buffers", Lars Hovgaard; Et Al, Pharmaceutical Formulation Development of Peptides and Proteins, Second Edition, CRC PRess, (20130000), page 155, XP055579993
OPPOSITION- "8.2.1. Buffers", Lars Hovgaard et al.,, PHARMACEUTICAL FORMULATION DEVELOPMENT OF PEPTIDES AND PROTEINS, Second Edition, CRC Press, (20130000), page 1pp, 155, XP055579993
OPPOSITION- "Alternative buffers for pharmaceutical anti-TNFalpha monoclonal antibody formulations [Elektronische Ressource]", PAPDEOTT002384, (20130206), page 10pp, XP009188701
OPPOSITION- "Alternative buffers for pharmaceutical anti-TNFalpha monoclonal antibody formulations [Elektronische Ressource]", PAPDEOTT002384,, (20130206), XP009188701
OPPOSITION- Anonymous, "Humira (adalimumab) injection, for subcutaneous use", Highlights of Prescribing Information, (20140900), page 80pp
OPPOSITION- David Sek, "Breaking old habits: Moving away from commonly used buffers in pharmaceuticals AU - David Sek", European Pharmaceutical Review, (20120710), page 12pp, URL: https://www.europeanpharmaceuticalreview.com/article/13699/breaking-old-habits-moving-away-from-commonly-used-buffers-in-pharmaceuticals/, XP055619226
OPPOSITION- David Sek, "Breaking old habits:Moving away from commonly used buffers in pharmaceuticals", European Pharmaceutical Review, (20120710), page 12pp, URL: https://www.europeanpharmaceuticalreview.com/article/13699/breaking-old-habits-moving-away-from-commonly-used-buffers-in-pharmaceuticals/, XP055619226
OPPOSITION- V.K. SHARMA et al., "Chapter 30: The Formulation and Delivery of Monoclonal Antibodies", V.K. SHARMA et al., Zhiqiang An, Therapeutic Monoclonal Antibodies: From Bench to Clinic,, john Wiley & Sons, Inc.,, (20090000), pages 675 - 709, XP055593299
OPPOSITION- V.K. SHARMA et al., "Chapter 30: The Formulation and Delivery of Monoclonal Antibodies", V.K. SHARMA et al., Zhiqiang An, Therapeutic Monoclonal Antibodies: From Bench to Clinic, John wiley & Sons, Inc.,, (20090000), pages 675 - 709, XP055593299

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents